Early gestational profiling of oxidative stress and angiogenic growth mediators as predictive, preventive and personalised (3P) medical approach to identify suboptimal health pregnant mothers likely to develop preeclampsia

• Published in: The EPMA journal 2021-12, Vol.12 (4), p.517-534
• Main Authors: Anto, Enoch Odame, Coall, David Antony, Addai-Mensah, Otchere, Wiafe, Yaw Amo, Owiredu, William K. B. A., Obirikorang, Christian, Annani-Akollor, Max Efui, Adua, Eric, Tawiah, Augustine, Acheampong, Emmanuel, Asamoah, Evans Adu, Wang, Xueqing, Opoku, Stephen, Boakye, Derick Kyei, Hou, Haifeng, Wang, Youxin, Wang, Wei
• Format: Article
• Language: English
• Subjects: Antioxidants; Biomarkers; Biomedical and Life Sciences; Biomedicine; Canada; China; Developing countries; Diagnosis; Endothelial growth factors; Ghana; Growth; Growth factors; Health aspects; Medicine/Public Health; Mortality; Oxidative stress; Preeclampsia; Pregnancy; Pregnant women; Tyrosine
• ISSN: 1878-5077; 1878-5085
• DOI: 10.1007/s13167-021-00258-x

Background P regnant women, particularly in developing countries are facing a huge burden of preeclampsia (PE) leading to high morbidity and mortality rates. This is due to delayed diagnosis and unrecognised early targeted preventive measures. Adapting innovative solutions via shifting from delayed to early diagnosis of PE in the context of predictive diagnosis, targeted prevention and personalisation of medical care (PPPM/3 PM) is essential. The subjective assessment of suboptimal health status (SHS) and objective biomarkers of oxidative stress (OS) and angiogenic growth mediators (AGMs) could be used as new PPPM approach for PE; however, these factors have only been studied in isolation with no data on their combine assessment. This study profiled early gestational biomarkers of OS and AGMs as 3 PM approach to identify SHS pregnant mothers likely to develop PE specifically, early-onset PE (EO-PE) and late-onset PE (LO-PE). Methods A prospective cohort of 593 singleton normotensive pregnant (NTN-P) women were recruited at 10–20th (visit 1) and followed from 21 weeks gestation until the time of PE diagnosis and delivery. At visit 1, SHS was assessed using SHS questionnaire-25 (SHSQ-25) and women were classified as SHS and optimal health status (OHS). Biomarkers of OS (8-hydroxy-2-deoxyguanosine [8-OHdG], 8-epi-prostaglansinF2alpha [8-epi-PGF2α] and total antioxidant capacity [TAC]) and AGMs (vascular endothelial growth factor [VEGF-A], soluble Fms-like tyrosine kinase-1 [sFlt-1], placental growth factor [PlGF] and soluble endoglin [sEng]) were measured at visit 1 and time of PE diagnosis. Results Of the 593 mothers, 498 (248 SHS and 250 OHS) returned for delivery and were included in the final analysis. Fifty-six, 97 and 95 of the 248 SHS mothers developed EO-PE, LO-PE and NTN-P respectively, versus 14 EO-PE, 30 LO-PE and 206 NTN-P among the 250 OHS mothers. At the 10–20th week gestation, unbalanced levels of OS and AGMs were observed among SHS women who developed EO-PE than LO-PE compared to NTN-P women ( p